ArticleHeart rhythm O22025
PLASMA Chile: A prospective, multicenter observational cohort study of patients with heart failure and reduced left ventricular ejection fraction.
Article in Heart rhythm O2, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inequities in access to life-saving cardiac devices for heart failure: a comparative analysis of Chile and Mexico.BMC cardiovascular disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chile has limited data on the treatment of patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF). Objective: This study aimed to evaluate adherence to the 2017 American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) guideline recommendations, identify barriers to cardiac implantable electronic device (CIED) use, and assess the association between CIED implantation and mortality. Methods: From March 2021 to December 2022, we conducted a prospective, multicenter observational cohort study across 6 hospitals. Adults aged ≥18 with HF with reduced EF ≤40% were enrolled. Sociodemographic, clinical, and treatment data were collected. Descriptive statistics and Cox univariable regression were performed. Results: The study included 243 patients with HF (73.3% male, median age 63 years), with comorbidities, including hypertension (67.1%), diabetes (30%), and obesity (37%); 41.2% had a history of myocardial infarction. At baseline, most patients received beta-blockers (96%), mineralocorticoid receptor antagonists (84%), and diuretics (65%). Of the 215 patients with LVEF ≤35%, 34.4% (n = 74) had a baseline CIED: 41.9% (n = 31) implantable cardioverter-defibrillators (ICD), 25.7% (n = 19) cardiac resynchronization therapy defibrillators (CRT-D), 17.6% (n = 13) CRT with a pacemaker, and 14.9% (n = 11) pacemaker. During follow-up, 27 of 75 eligible patients received ICD or CRT-D as recommended by the 2017 ACC/AHA/HRS guideline, whereas 38 did not because of access issues. There were 26 deaths, with no significant mortality differences between those with and without ICD or CRT-D. Conclusion: In Chile, patients with HF with reduced LVEF receive pharmacological therapy consistent with international standards; however, they face access barriers to CIEDs, which are underutilized despite their benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.